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Background/aim: The thrombolysis in myocardial infarction (TIMI) risk score (TRS), and the TIMI risk index (TRI) have been reported
in coronary artery disease patients. We investigated whether admission TRI is associated with no-reflow (NRF) in patients undergoing
primary percutaneous coronary intervention (p-PCI).
Materials and methods: ST-segment elevation myocardial infarction (STEMI) patients treated with p-PCI were included in the study.
TRI was calculated on admission using specified variables. We defined the angiographic NRF phenomenon as a coronary TIMI flow
grade of ≤2 after the vessel was recanalized or a TIMI flow grade of 3 together with a final myocardial blush grade (MBG) of <2 in a
manner as described in previous studies.
Results: A total of 371 patients (aged 62 ± 14 years; 73/27 men to women ratio) who underwent p-PCI were enrolled in the study. In
terms of age, NRF patients were older than reflow patients (P < 0.017 for MBG). Killip class III-IV designations were more common in
NRF patients (P = 0.029 for MBG). TRI (P = 0.014 for MBG) values were significantly greater in the NRF group. TRI was an independent
predictor of NRF according to MBG flow (P = 0.003, B = –0.035, Exp B = 0966, 95% CI, 0.944–0.988).
Conclusion: Admission TRI may predict the development of NRF phenomenon after p-PCI in patients with acute STEMI.
Key words: ST-segment elevation myocardial infarction, global registry of acute coronary events risk score, thrombolysis in myocardial
infarction risk score, thrombolysis in myocardial infarction risk index, no-reflow phenomenon, primary percutaneous coronary
intervention

1. Introduction
Coronary artery disease (CAD) and acute myocardial infarction (AMI) are major causes of death and morbidity
worldwide (1). Rapid restoration of coronary blood flow
to the jeopardized myocardium is the crux of therapy after
AMI. The invention and usage of stents have made percutaneous coronary intervention (PCI) a safe, effective,
and preferred treatment of ST-segment elevation myocardial infarction (STEMI) (2). However, even after patency
of an infarcted artery was successfully achieved via stent
implantation, sufficient myocardial reperfusion was not
observed in 2.3% to 29% of patients in the setting of AMI,
often called the no-reflow (NRF) phenomenon (3–5). Despite the mechanical opening of the infarct-related artery
(IRA), early postinfarction complications and in-hospital
long-term morbidity and mortality rates increased in patients who developed NRF (6–8). The mechanisms of NRF
are complex and multifactorial; the most probable causes
include a combination of platelet aggregation, distal em* Correspondence: halitacet@gmail.com
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bolization, microvascular vasoconstriction, neutrophil
plugging, and tissue edema (9). Noninvasive markers of
the NRF phenomenon may thus provide important prognostic information. Recently, one of the major issues cardiologists have been working on is risk prediction in patients
with STEMI to identify NRF. (6–8,10). A large number of
scoring systems and laboratory parameters have been used
in clinical practice. Nevertheless, those interested in cardiovascular medicine still need an easily accessible, cost
effective, and noninvasive predictor to carry out risk stratification by determining NRF in acute coronary syndrome
(ACS) patients. In order to identify high-risk patients with
ACS, various risks classification systems and scoring systems are used frequently (11–14). Prediction of early and
late mortality in hundreds of thousands of patients has
been shown by the in-hospital death global registry of
acute coronary events (GRACE) risk score (GRS) and the
thrombolysis in myocardial infarction (TIMI) risk score
(TRS) (13,14). Recently, the TIMI risk index (TRI) (which
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can predict mortality, may be easier to assess and can be
scored with fewer parameters in patients with non-STsegment elevation ACS (NSTE-ACS) and patients with
STEMI) was improved. This index has been shown to be
useful and helpful in many studies (15,16). Many studies
have investigated the relationship between GRS, TRI, and
ACS (1,17–19), but none have addressed the association
between TRI, TRS, GRS, and NRF in patients with STEMI.
We investigated whether preintervention TRI, TRS, and
GRS are related to coronary NRF in patients with STEMI
who underwent primary percutaneous coronary intervention (p-PCI).
2. Materials and methods
2.1. Study population
A total of 900 patients who presented with STEMIs and
underwent p-PCI within 12 h of symptom onset between
January 2012 and February 2014 were included in this
retrospective study. STEMI was defined based on the
criteria used by the American College of Cardiology and
the European Society of Cardiology (20): an increase in
troponin I > 1 ng/mL, a new ST elevation as measured
from the J-point in 2 or more contiguous leads with leads
V1, V2, and V3 measuring at least 0.2 mV or at least 0.1
mV in the remaining leads during the first 12 h after
symptom onset, or newly developed left bundle branch
block (LBBB) pattern.
Patients with malignancy, bleeding diathesis,
hematological disease, severe liver disorder, autoimmune
disease, severe valvular disease, and inflammatory or
infectious diseases were excluded from the study. In
addition, patients on the following medications were not
included in the study: corticosteroids, cytotoxic drugs,
thrombolytic therapy, glycoprotein IIb/IIIa inhibitors,
and diuretics. Patients who were not treated with p-PCI,
did not undergo follow-up blood work, or had poor
echocardiographic windows were also excluded from the
investigation. As a result, a total of 371 patients formed the
study group.
All patients underwent physical examination and
coronary risk factor assessment through a complete
medical history. Additionally, Killip class examinations of
all patients were recorded (21).
Demographic data and variables to determine TRS
according to age, diabetes mellitus (DM)/hypertension
(HT) or angina, heart rate of <100 bpm, systolic blood
pressure (SBP) of <100 mmHg, Killip class II-IV, weight
of <67 kg, anterior MI or LBBB presentation, and latency
of >4 h were recorded (22). Calculation of the TRS was
performed with a computer program (http://www.mdcalc.
com/timi-risk-score-for-stemi/).
The determination of GRS points including age,
creatinine, heart rate, SBP, Killip class, cardiac arrest on

admission, elevated cardiac markers, and ST-segment
deviation were recorded (14); the calculation of GRS
was performed using a computer program (www.
outcomesumassmed.org/grace/acs_risk/acs_risk_content.
html).
The TRI of patients were calculated by the formula
“Heart rate × (age÷10)2÷SBP”.
During the in-hospital follow-up period patients were
monitored for major adverse cardiac events (MACEs).
Cardiogenic shock, new advanced heart failure, pulmonary
edema, complete atrioventricular block (AVB) requiring
a temporary pacemaker, severe ventricular arrhythmia,
and in-hospital mortality during the post-PCI follow-up
period were regarded as MACEs. An in-hospital mortality
was only considered a MACE if the death was caused by
myocardial infarction, cardiac arrest, or other cardiacrelated causes. Cardiogenic shock was defined as: marked
and persistent hypotension lasting more than 30 min with a
SBP less than 80 mmHg and signs of hypoperfusion due to
left ventricular dysfunction, right ventricular infarction, or
cardiac mechanical complications. If the patient qualified
for a New York Heart Association functional classification
of III or greater, it was considered new-onset advanced
heart failure. Severe ventricular arrhythmias (ventricular
tachycardia, ventricular fibrillation, or asystole) were
considered to be MACEs if they occurred within 48 h of
onset.
2.2. Blood samples and echocardiography
Venous blood samples were collected when the patient
was admitted to the emergency department or intensive
coronary care unit (ICCU) before p-PCI. Hematologic
indices were calculated using an automated hematology
analyzer system (Abbott Cell-Dyn 3700; Abbott
Laboratory). Absolute cell counts were utilized to perform
subsequent analyses. The neutrophil to lymphocyte ratio
(NLR) was calculated as the ratio of the neutrophils and
lymphocytes, both obtained from the same automated
blood sample at admission. Total cholesterol, high-density
lipoprotein, low-density lipoprotein, triglycerides, and
creatinine levels were measured with the Abbott Architect
C16000 autoanalyzer (Abbott Laboratory). Fasting lipid
panels were obtained after an overnight fast.
Transthoracic two-dimensional echocardiography was
performed upon admission to the ICCU to determine
left ventricular ejection fraction, left ventricular systolic
diameter, left ventricular diastolic diameter, and left atrial
diameter (Vivid S6, GE Medical Systems).
2.3. Coronary angiography (TIMI and myocardial blush
grade (MBG) flow)
All patients underwent selective coronary angiography
using the Judkins technique. PCI procedures were
performed with a standard femoral approach using a 7
Fr guiding catheter. Coronary blood flow patterns after
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p-PCI were subject to a thorough evaluation on the basis
of TIMI flow grade, using grades 0, 1, 2, and 3 (23). The
final TIMI flow grade and MBG were assessed using
standard methods. Two cardiologists who were blinded to
the patients’ clinical situations assessed the postprocedural
TIMI flow grade of the IRA. We defined the angiographic
NRF phenomenon as a coronary TIMI flow grade of
≤2 after the vessel was recanalized or TIMI flow grade
3 together with a final MBG of <2, in the same manner
as described in previous studies (24,25). For all study
participants, only one artery was identified as the IRA.
CAD was defined as greater than 50% stenosis in one of
the major coronary arteries.
2.4. Statistical analysis
All analyses were performed with SPSS for Windows
version 18.0. Continuous variables were expressed as
means ± standard deviation and categorical variables were
expressed as percentages. The two-sample Kolmogorov–
Smirnov test assessed whether continuous variables
followed a normal distribution. Comparisons between
categorical and continuous variables between the reflow
and NRF groups were performed using the χ2 or Fischer’s
exact test and independent samples t-test or Mann–
Whitney U-test, respectively. Statistical significance was
defined as P < 0.05.
Multivariate stepwise forward logistic regression
analysis was used to assess independent predictors of
postprocedural NRF according to MBG flow. All variables
that were significant predictors were included in the
logistic regression model; the results were expressed as the
odds ratio (OR) with the corresponding 95% confidence
interval (CI).
The study protocol was reviewed and approved by the
Ethics Committee in accordance with the Declaration of
Helsinki.
3. Results
A total of 371 patients were included in the data analysis.
Of all the study participants, 17.5% according to MBG
flow were in the NRF group, while the remaining were
stratified into the reflow group. Baseline demographic
characteristics and cardiac risk scores on admission of
patients for TIMI and MBG flow after p-PCI results
organized according to reflow grouping are shown in
Tables 1 and 2. No significant differences regarding known
atherogenic risk factors, prehospital medication, location
of STEMI, SBP, and heart rate on admission were identified
between the groups. NRF patients were older than reflow
patients (P < 0.018 for TIMI flow, P < 0.017 for MBG flow)
and Killip class III-IV designations were more common
in NRF patients (P = 0.009 for TIMI flow, P = 0.029 for
MBG). TRS (P = 0.015 for TIMI flow, P = 0.043 for MBG
), GRS ( P < 0.001 for TIMI flow, P = 0.004 for MBG ), and
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TRI ( P = 0.002 for TIMI flow, P = 0.014 for MBG ) values
in the NRF group were significantly greater than those in
the reflow group.
Angiographic findings according to reflow grouping
are shown in Tables 3 and 4.
In-hospital mortality and MACEs were also
significantly higher in the NRF group. Similarly, inhospital cardiogenic shock, severe ventricular arrhythmia,
and cardiopulmonary resuscitations were more common
in the NRF patients (Tables 5 and 6).
Multivariate binary forward stepwise logistic
regression analysis revealed that a high level of TRI was an
independent predictor of NRF according to MBG flow (P
= 0.003 B = –0.035, Exp B = 0966, 95% CI, 0.944–0.988).
4. Discussion
In the present study we showed that increased TRI, TRS,
and GRS on admission were significantly associated with
the development of angiographic NRF phenomenon
in patients with acute STEMI who underwent p-PCI.
Moreover, TRI was a significant and independent predictor
of NRF. We also showed the Killip class.
Primary PCI is the recommended treatment for
patients with acute STEMI. In 2008 the Stent for Life
(SFL) initiative was launched by the European Association
of Percutaneous Cardiovascular Interventions and
EuroPCR in partnership with the European Society of
Cardiology Working Group on Acute Cardiac Care and
country-specific national cardiac societies. The aim was
to promote the prioritization of PCI treatment for those
who will benefit most, namely STEMI patients. The
following countries are currently participating: Bulgaria,
Egypt, France, Greece, Italy, Portugal, Romania, Serbia,
Spain, and Turkey (26). Preliminary reports suggest that
major increases have been seen in the numbers of p-PCI
treatments performed, with some countries reporting very
significant increases in p-PCI use between 2008 and 2010.
Improvements in STEMI mortality rates have also been
observed. The number of p-PCI treatments performed
in Europe has steadily increased over the past decade.
However, a European survey from 2007 reported that
only 40%–45% of European STEMI patients were treated
with p-PCI, with large variations in treatment availability
between countries (27). The challenges of introducing
new technologies into clinical practice can be substantial
and include a complex mix of medical, organizational,
patient-related, regulatory, and economic factors (28).
There are 207 PCI capable centers in Turkey, shared
among government hospitals, university hospitals, and
private hospitals. P-PCI is performed 24/7 in 82 of the 207
centers. In March 2011, the Ministry of Health declared
p-PCI as the first choice treatment for STEMI patients
nationally, if transport time is less than 90 min. Since
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Table 1. Baseline demographic characteristics and cardiac risk scores of patients for TIMI flow after primary PCI.
Variables

Reflow

No-reflow

P value

Age, years

60.8 ± 13.6

65.2 ± 13.4

<0.018*

Males, n (%)

224 (73)

45 (69)

0.515

Hypertension, n (%)

108 (35)

24 (37)

0.803

Diabetes mellitus, n (%)

68 (22)

20 (31)

0.141

Smoking, n (%)

173 (57)

29 (45)

0.080

Hyperlipidemia, n (%)

19 (6)

4 (6)

0.987

Family history, n (%)

60 (20)

12 (19)

0.832

Previous MI or CAD, n (%)

20 (7)

0 (0)

0.034

Previous PCI, n (%)

18 (6)

4 (6)

0.559**

Aspirin use, n (%)

223 (77)

45 (74)

0.634

Clopidogrel, n (%)

154 (53)

24 (40)

0.054

Beta blocker, n (%)

28 (9)

7 (1)

0.691

ACE inhibitors, n (%)

31 (10)

5 (8)

0.546

Statin, n (%)

20 (7)

5 (8)

0.453

Enoxaparine, n (%)

274 (90)

61 (94)

0.287

I-II

274 (94)

51 (83)

III-IV

17 (6)

10 (17)

Admission SBP (mmHg),

127.6 ± 23.9

122.6 ± 25.6

0.128

Admission heart rate (bpm)

83.0 ± 15.9

86.1 ± 20.7

0.264

Duration of chest pain (hour)

5.6 ± 4.1

6.3 ± 3.8

0.210

Anterior, n (%)

131 (45)

30 (49)

Nonanterior, n (%)

160 (55)

31 (51)

TIMI risk score

3.8 ± 2.2

4.8 ± 2.9

0.015

GRACE risk score

151.7 ± 35.4

177.0 ± 51.4

<0.001*

TIMI risk index

25.6 ± 12.5

32.1 ± 15.8

0.002*

Previous history

Prehospital medication

Killip class on presentation, n (%)
0.009**

Location of STEMI
0.553

Cardiac risk scores on admission

Fischer Exact; Other Statics Student’s t -test; χ2 test; *Mann–Whitney U test; Values are means ± SD or n (%).

**

Turkey joined the SFL initiative, the number of p-PCI
performed has increased significantly in ten pilot cities. In
2010, 85% of STEMI patients were treated with p-PCI. In
addition, a STEMI network was created with collaboration
between a number of invasive centers, noninvasive
hospitals, ambulances, and emergency systems (26).

Rapid restoration of coronary flow to the jeopardized
myocardium has become an essential part of therapy
after STEMI. P-PCI has also been found to significantly
improve the survival of these patients (29). Despite an
open IRA, breakdown of obstruction to the coronary
microvasculature can markedly decrease blood flow to the
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Table 2. Baseline demographic characteristics and cardiac risk scores of patients for MBG after primary PCI.
Variables

Reflow

No-reflow

P value

Age, years

60.9 ± 13.6

66.0 ± 13.8

<0.017*

Males, n (%)

241 (74)

28 (62)

0.099

Hypertension, n (%)

115 (35)

17 (38)

0.742

Diabetes mellitus, n (%)

73 (22)

15 (33)

0.106

Smoking, n (%)

1783 (56)

19 (42)

0.079

Hyperlipidemia, n (%)

20 (7)

3 (6)

0.546**

Family history, n (%)

66 (20)

6 (13)

0.272

Previous MI or CAD, n (%)

20 (6)

0 (0)

0.070**

Previous PCI, n (%)

20 (6)

2 (4)

0.486**

Aspirin use, n (%)

239 (77)

29 (69)

0.251

Clopidogrel, n (%)

160 (52)

18 (43)

0.287

Beta blocker, n (%)

31 (10)

4 (9)

0.574

ACE inhibitors, n (%)

33 (7)

3 (10)

0.338

Statin, n (%)

21 (6)

4 (9)

0.359

Enoxaparine, n (%)

294 (90)

41 (91)

0.551

I-II

290 (93)

35 (83)

III-IV

20 (7)

7 (17)

Admission SBP (mmHg),

127.4 ± 23.9

122.3 ± 26.0

0.193

Admission heart rate (bpm)

83.4 ± 15.9

84.9 ± 23.5

0.686

Duration of chest pain (hour)

5.6 ± 4.1

6.4 ± 3.8

0.255

Anterior, n (%)

144 (47)

17 (41)

Nonanterior, n (%)

166 (53)

25 (59)

TIMI risk score

3.9 ± 2.2

4.9 ± 3.1

0.043

GRACE risk score

152.9 ± 35.9

178.4 ± 56.0

0.004*

TIMI risk index

25.9 ± 12.6

32.6 ± 17.2

0.014*

Previous history

Prehospital medication

Killip class on presentation, n (%)
0.029**

Location of STEMI
0.466

Cardiac risk scores on admission

Fischer Exact; Other Statics Student’s t -test; χ2 test (%), *Mann–Whitney U test; Values are means ± SD or n (%).

**

infarct zone. This effect is known as the NRF phenomenon
(30,31). Coronary flow decreases in elderly patients,
menopausal women, and patients with coronary risk factors
(32). This phenomenon is strongly correlated with shortand long-term morbidity and mortality in the settings
of STEMI (33). In our study, we showed that NRF was
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significantly related to in-hospital mortality and MACEs.
The pathophysiology of the NRF phenomenon has not been
fully clarified and its etiology appears to be multifactorial.
Some of the contributing factors in the occurrence of NRF
are distal atherothrombotic embolization, mechanical
microvascular leukocytes, platelet plugs in situ thrombosis,
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Table 3. Angiographic findings of patients for TIMI flow after primary PCI.
Reflow

No-reflow

LAD, n (%)

139 (46)

37 (57)

RCA, n (%)

114 (37)

25 (39)

CX, n (%)

53 (17)

31 (4)

1 vessel, n (%)

134 (44)

24 (37)

>1 vessel n, (%)

171 (56)

41 (63)

P value

Culprit lesion
0.027

Number of coronary arteries narrowed
0.299

CX, circumflex coronary artery; LAD, left descendant coronary artery; RCA, right coronary artery.
Table 4. Angiographic findings of patients for MBG after primary PCI.
Reflow

No-reflow

LAD, n (%)

153 (87)

23 (13)

RCA, n (%)

119 (86)

20 (14)

CX, n (%)

54 (96)

2 (4)

1 vessel, n (%)

143 (91)

15 (9)

>1 vessel n, (%)

182 (86)

30 (14)

P value

Culprit lesion
0.097

Number of coronary arteries narrowed
0.175

CX, circumflex coronary artery; LAD, left descendant coronary artery; RCA, right coronary artery.
Table 5. In-hospital adverse outcomes of patients TIMI flow after primary PCI.
Reflow

No-reflow

P value

In-hospital MACE, n (%)

56 (17)

28 (44)

<0.001

Advanced Heart Failure, n (%)

17 (6)

7 (11)

0.121

Advanced pulmonary edema, n (%)

10 (4)

6 (9)

0.043*

Cardiogenic shock, n (%)

17 (6)

13 (20)

<0.001*

Complete atrioventricular block requiring transient pacemaker

13 (4)

5 (8)

0.193*

Serious ventricular arrhythmia

21 (7)

12 (19)

0.003

Cardiopulmonary resuscitation, n (%)

24 (8)

19 (29)

<0.001

Hospitalization duration (days)

5.3 ± 4.7

6.0 ± 6.2

0.402

In-hospital mortality, n (%)

20(7)

17(26)

<0.001

: Fischer exact test; MACE: major adverse cardiac event.

*
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Table 6. In-hospital adverse outcomes of patients MBG after primary PCI.
Reflow

No-reflow

P value

In-hospital MACE, n (%)

62 (19)

22 (50)

<0.001

Advanced Heart Failure, n (%)

20 (6)

4 (9)

0.329*

Advanced pulmonary edema, n (%)

13 (4)

3 (7)

0.305*

Cardiogenic shock, n (%)

19 (6)

11 (24)

<0.001*

Complete atrioventricular block requiring transient pacemaker

13 (4)

5 (11)

0.053

Serious ventricular arrhythmia

23 (7)

10 (22)

0.003*

Cardiopulmonary resuscitation, n (%)

27 (8)

16 (36)

<0.001

Hospitalization duration (days)

5.3 ± 4.6

6.0 ± 7.2

0.543

In-hospital mortality, n (%)

22 (7)

15 (33)

<0.001*

: Fischer Exact test; MACE: major adverse cardiac event.

*

ischemic endothelial edema and damage, vasospasm,
free oxygen radicals, and susceptibility of the coronary
microcirculation to injury (9,34,35). The close interplay
between inflammation, coagulation, and atherosclerosis
progression has become a field of intensive research. An
increased inflammatory activity in the setting of STEMI
may be one of the underlying NRF mechanisms. In fact,
an elevated leukocyte–platelet interaction at the site of the
plaque rupture may play a negative role in distal myocardial
reperfusion by activating further inflammation. Botto et
al. (36) showed an increased leukocyte–platelet functional
interaction in STEMI at the site of plaque rupture relative
to the systemic circulation, which may be one of the
pathogenic mechanisms liable for NRF phenomenon.
Thus, both locally increased inflammatory markers and
leukocyte–platelet coaggregates at the site of the plaque
rupture may be pathogenic mechanisms responsible for
the angiographic NRF phenomenon after p-PCI in STEMI.
Effective risk stratification is integral to the
management of patients with ACS (37). Even among
patients with STEMI for whom initial therapeutic options
are well-defined, patient risk characteristics can affect
early therapeutic decision making (38–40). There are few
models that have integrated weighing information from
multivariate regression in a fashion similar to the TRS,
TRI, and GRS. The GRS has been recognized as a validated
predictor of adverse cardiovascular disease events (19,41).
GRS includes some variables, but does not include the
properties of coronary lesion and inflammatory markers.
The TRS for STEMI is a clinical stratification calculated
with data obtained from hospital presentations that can
easily classify low- and high-risk patients (42). The TRS was
validated prospectively in various studies. The analysis was
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subsequently validated in an unselected patient population
in the National Registry of Myocardial Infarction (43)
and showed a strong predictive value for mortality in
patients treated with thrombolytic therapy (44). TRS has
been shown to be a predictor of MACEs in patients with
STEMI (18). The TRS serves as a prognostic calculator
that discriminates high-risk patients with a combination
of baseline variables that are part of the routine medical
evaluation (22). Moreover, the relationship between
TRS and the severity of CAD has been shown in several
studies. TRS was compared with the results of coronary
angiography in 683 patients with NSTE-ACS; for each
increased risk category, the 3-vessel disease was shown to
be more frequent (1). In the PRISM-PLUS study of 1491
patients with ACS, it was shown that there were more
severe coronary lesions and left main coronary lesions in
patients with high TRS compared with those with low TRS
(45). The TRS reliably identified patients who were at high
risk, while maintaining good discriminatory capacity in
the low-risk range, where smaller absolute differences are
more likely to impact clinical decisions. The TRS includes
some variables, but does not include inflammatory markers
and the properties of coronary lesions. Another one of the
important scoring systems used in risk stratification in
patients with ACS is TRI. It has been shown to be useful
and helpful in many studies with large patient populations.
It was derived from observed risk relations among 13,253
patients enrolled in the Intravenous NPA for the treatment
of infarcting myocardium early (In TIME II) randomized
trial of lanoteplase versus alteplase as reperfusion therapy
for STEMI (46). The prognostic discriminatory capacity
of this index was demonstrated (15,16,46). The TRI
was a strong and independent predictor of mortality at
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24 h. It was validated in an external data set of STEMI
patients from the TIMI-9 trials that showed both a high
discriminatory capacity and concordance between the
observed 30-day mortality and the predictions based on
the In TIME II data (47). Rathore et al. (48) focused on
this very point after evaluating the discrimination and
calibration performance of the TRI in a community-based
cohort of elderly patients taken from the Cooperative
Cardiovascular Project. We applied the TRS, TRI, and GRS
for STEMI in a group of patients who underwent p-PCI
and showed that an increase in these scores was associated
with increased frequency of angiographic NRF.
To our knowledge, the relationship of TRI, TRS,
and GRS with NRF for STEMI has not been previously
investigated. Our results demonstrated for the first time

the predictive value of these scores for NRF in patients
with STEMI. In the present study, we think that with the
help of the calculation of these scores in patients admitted
to the emergency department with ACS, information
about NRF of the CAD may be obtained.
Some limitations of our study include its retrospective
nature and relatively small number of patients. Our study’s
population was also from a single center. Due to a male
dominance in the patients in our study, the results may not
be applicable to female patients.
The TRI, GRS, and TRS are routinely used for
stratification of patients with ACS. Our study showed
that these scores were significantly associated with NRF
in patients with STEMI. We think that these findings can
guide further clinical practice.
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